2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Karen A. Hicks(Center for Drug Evaluation and Research), Robert J. Temple(Center for Drug Evaluation and Research), Hylton V. Joffe(Center for Drug Evaluation and Research), Shari Targum(Center for Drug Evaluation and Research), Roxana Mehran(Icahn School of Medicine at Mount Sinai), John R. Teerlink(San Francisco VA Medical Center), Billy Dunn(Center for Drug Evaluation and Research), Andrew Farb(Memorial Hermann), Eldrin F. Lewis(Brigham and Women's Hospital), Mary Thanh Hai(Center for Drug Evaluation and Research), John J.V. McMurray(Western Infirmary), Kenneth Rosenfield(Massachusetts General Hospital), Marc A. Pfeffer(Brigham and Women's Hospital), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Paul Burton(Janssen (United States)), Alexandra J. Lansky(Yale University), Steven E. Nissen(Cleveland Clinic), Hung Hung(Center for Drug Evaluation and Research), Steven R. Steinhubl(Scripps Research Institute), Scott D. Solomon(Brigham and Women's Hospital), Donald E. Cutlip(Beth Israel Deaconess Medical Center), David A. Morrow(Brigham and Women's Hospital), Michael R. Jaff(Harvard University), Steven S. Brooks(Data Voice Exchange (United States)), Bernard Chaitman(Saint Louis University), Martin Landray, Laura Mauri(Brigham and Women's Hospital), James E. Tcheng(Duke University), Akshay S. Desai(Brigham and Women's Hospital), Christopher J. White(Ochsner Medical Center), Cathy Sila(University Hospitals of Cleveland), John R. Marler(Center for Drug Evaluation and Research), Stephen D. Wiviott(Brigham and Women's Hospital), Michaël Domanski(Mount Sinai Hospital), Christopher M. O’Connor(Alaska Heart and Vascular Institute), A. Michael Lincoff(Cleveland Clinic), Norman Stockbridge(Center for Drug Evaluation and Research), C. Michael Gibson(Brigham and Women's Hospital)
Circulation
February 26, 2018
Cited by 712


Related Papers